# Nanobody Shows Promise in Myasthenia Gravis

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/aanemvideopearls/123808) · 2026-11-10 · Medicine
Page: https://themorning.science/story/nanobody-shows-promise-in-myasthenia-gravis-6be4a6cf6a1516dd
Kind: research · Impact: medium

## In brief

- Results from the phase III PREVAIL trial were presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting.
- The investigational drug is gefurulimab, a nanobody given once weekly.
- The source excerpt reports a significant result but is truncated, so the outcome details are not confirmed here.

## Why it matters

It reports phase III data for a once-weekly nanobody in myasthenia gravis, a signal for neurology researchers following antibody-based treatments for this autoimmune disease.

## Coverage

- [Nanobody Shows Promise in Myasthenia Gravis](https://www.medpagetoday.com/meetingcoverage/aanemvideopearls/123808) — MedPageToday.com - medical news for physicians, 2026-11-10

Tags: myasthenia gravis, nanobody, gefurulimab, clinical trial, neurology

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science